Pfizer
Karen Zimmerman is an accomplished professional with extensive experience in qualitative research, particularly in the pharmaceutical and healthcare industries, as well as telephony and cable services. Since 1987, Zimmerman has served as President of Zimmerman Associates, focusing on delivering high-quality research and ensuring client satisfaction. Prior to this role, Zimmerman was President of National Analysts from September 1976 to September 1987 and held the position of Senior Analyst. Karen Zimmerman's academic background includes a degree from Penn State University, completed between 1971 and 1975.
This person is not in any teams
This person is not in any offices
Pfizer
619 followers
Pfizer Inc. is a research-based, global biopharmaceutical company. They apply science and their global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. They work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Pfizer collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Pfizer was founded in 1942. Most of Pfizer’s revenues come from the manufacture and sale of biopharmaceutical products. They believe that their medicines and vaccines provide significant value for healthcare providers and patients, through improved treatment of diseases, improvements in health, wellness and productivity as well as by reducing other healthcare costs, such as emergency room or hospitalization. Pfizer is committed to fulfilling their purpose: Breakthroughs that change patients’ lives. Their purpose fuels everything they do and reflects both their passion for science and commitment to patients. Pfizer’s growth strategy is driven by five “Bold Moves” that help them deliver breakthroughs for patients and create value for shareholders and other stakeholders: 1. Unleash the power of our people; 2. Deliver first-in-class science; 3. Transform our go-to-market model; 4. Win the digital race in pharma; and 5. Lead the conversation.